There are 384 papers on osteocalcin in aging research: 95 trials and 91 observational studies in people, 133 in animals, 15 in cells, 48 reviews. The newest story, Nov 12, 2026: “Natural compound curbs bone breakdown by lab-grown cells”.
Human observational studies associate osteocalcin with bone mineral density, frailty in women, and osteosarcopenia. Human exercise trials often report increases, while hormone treatment trials report increases or decreases depending on the treatment. An association with vascular dementia does not survive correction for multiple testing; an alpha-ketoglutarate trial in postmenopausal women with osteopenia shows no clear effect on osteocalcin.
124 findings in 103 papers from 1988 to 2026, 8 of them since April 2026
“positive association of OC (r = 0.32, p = 0.022) with BMD at the lumbar spine were identified after resveratrol”
Resistance training increases osteocalcin in humans (physically active) (p = 0.015).
“Significant Exercise × Time interactions were shown for osteocalcin (p = 0.015), OPG (p = 0.021), and sclerostin (p = 0.002), with higher concentrations 24 h after resistance exercise than following endurance exercise.”
Human trialphysically activeserum24 h post-exercisefemalesn = 13
Resistance training decreases osteocalcin in aging ovariectomized rats.
“there was also a significant decrease in plasma levels of OCN (p=0.001 and 0.002) and OPG (p=0.003 and 0.014), compared with animals in the NT-Veh group.”
Resveratrol showed no clear effect on osteocalcin in humans (no significant reduction).
“Pooling six RCTs (eight treatment arms with 264 subjects) together identified no significant reduction of serum Ca, osteocalcin, C-terminal telopeptide of type I collagen, and procollagen I N-terminal propeptide values”
Resveratrol increases osteocalcin in ovariectomized rats, partially reversing OVX-induced decrease.
“Relative levels of OCN and Runx2, ALP activity and calcification ability decreased in OVX group relative to sham group, which were partially reversed by RES treatment.”
Cholecalciferol showed no clear effect on osteocalcin in humans.
“cholecalciferol supplementation alone throughout winter did not affect bone turnover markers in apparently healthy young and elderly adults, even when stratified by VDR genotype.”
Somatropin increases osteocalcin in humans (osteoporotic) (88%).
“Mean levels of the bone formation markers S-osteocalcin and S-procollagen type I propeptide increased maximally by 88 and 36% respectively after 9-12 months”
Somatropin increases osteocalcin in humans (10.3 +/- .86 vs. 8.0 +/- 0.5 micrograms/L; P less than 0.05).
“A rise in serum osteocalcin (10.3 +/- .86 vs. 8.0 +/- 0.5 micrograms/L; P less than 0.05) was accompanied by increased urinary excretion of hydroxyproline”
Limosilactobacillus reuteri showed no clear effect on osteocalcin in humans (prednisolone treatment) (14.2 (95% CI −7.8 to 36.3, p =.21)).
“After 7 d of treatment with prednisolone, the adjusted mean difference between L. reuteri treatment and placebo in percentage change of bone status indices was 14.2 (95% CI −7.8 to 36.3, p =.21) for osteocalcin”
Human trialprednisolone treatment30 d (27 d minimum)n = 50
Limosilactobacillus reuteri showed no clear effect on osteocalcin in healthy young adults receiving oral prednisolone (14.2 (95% CI -7.8 to 36.3), p = .21).
“or in osteocalcin levels (14.2 [-7.8-36.3], p = .21)”
Human trialin healthy young adults receiving oral prednisolone1 × 1010 CFU/d2 wkn = 46
Walking increases osteocalcin in humans (8.51 ± 2.28 ng/mL to 9.39 ± 2.97 ng/mL).
“When comparing the findings after the intervention to those before the intervention, significant increases were observed in the serum concentration of OC (8.51 ± 2.28 ng/mL to 9.39 ± 2.97 ng/mL, p < 0.1) and the serum concentration ICTP (4.45 ± 2.58 ng/mL to 5.31 ± 2.92 ng/mL, p < 0.1).”
Equol + resveratrol improves osteocalcin in humans.
“Likewise, a significant change in the concentrations of OC and BAP compared to both the baseline and placebo (p ≤ 0.0001 for all, C,D) was observed after 12 months.”
Osteocalcin is linked with higher dementia prediction C index in humans (Adding osteocalcin to the prediction model; fivefold cross-validation) (C index from 0.84628 to 0.84642; ΔC = 0.00014).
“Adding OCN changed the mean fivefold cross-validated C index from 0.84628 to 0.84642 (ΔC = 0.00014).”
HumansAdding osteocalcin to the prediction model; fivefold cross-validation
International journal of environmental research and public health·
Upstream
1
Ketosis suppression
↑upin humans1
1 study
ketosis suppression increases osteocalcin in humans (33.84 ng/mL (± 13.66) to 55.31 ng/mL (± 29.71, P2)).
“tOCN significantly increased after P1 from 33.84 ng/mL (± 13.66) to 55.31 ng/mL (± 29.71, P2, p = 0.0138; ), and then significantly decreased following the removal of SuK (P3) to 34.02 ng/mL (± 12.05, p = 0.0253) compared to P2, returning to similar baseline P1 values.”
Osteocalcin is linked with a higher risk of osteosarcopenia in humans (adjusted model).
“In the multivariable logistic regression model, OC and CTX were associated with increased likelihood of osteosarcopenia [adjusted OR= 1.023(1.002-1.045 for OC, 4.363(1.389-15.474 for CTX)].”
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·
Type 2 diabetes is associated with osteocalcin in patients with T2DM and/or CVD.
“Patients with type 2 diabetes mellitus (T2DM) and/or cardiovascular disease (CVD), conditions of hyperinsulinaemia, have lower levels of osteocalcin”
Osteocalcin is associated with bone mineral density in humans.
“The data showed that BMD status and vitamin D levels correlated positively with serum levels of osteocalcin and total calcium and negatively with BMI and s-BAP, as shown in Table.”
Osteocalcin is associated with bone mineral density in humans (very elderly Chinese men).
“The three turnover markers were moderately correlated to each other (P < 0.001), and all negatively associated with the bone mineral density of three sites (P < 0.05).”
Osteocalcin predicts osteoporosis in humans (Shanghai Chinese postmenopausal women) (AUC 0.746).
“the best predictors for postmenopausal osteoporosis in Shanghai Chinese postmenopausal women were osteocalcin (OC) and procollagen type 1 N-terminal propeptide (P1NP)”
HumansShanghai Chinese postmenopausal womenfemalesn = 331
Osteocalcin is associated with primary osteoporosis in humans (Community-dwelling middle-aged and older women).
“elevated OST and PINP levels and imbalanced constitutions such as qi deficiency/yang deficiency/yin deficiency/damp-heat/blood stasis/qi stagnation indicated higher risk.”
HumansCommunity-dwelling middle-aged and older womenfemalesn = 1,186
Osteocalcin is associated with lumbar spine bone mineral density in humans after resveratrol (r = 0.32).
“Along with the significant inverse association of NTproCNP with BMD, there was a significant positive association of OC (r = 0.32, p = 0.022) with BMD in the lumbar spine.”
Lab experiments found that carabrone reduced bone-resorbing activity while having limited effects on measured cell signals involved in coordinating bone formation.Lab experiments found that carabrone reduced bone-resorbing activity while having limited effects on measured cell signals involved in coordinating bone formation.
Experiments found that mice lacking SIRT5, a protein that modifies other proteins, had poorer bone formation and more severe bone loss than normal mice.Experiments found that mice lacking SIRT5, a protein that modifies other proteins, had poorer bone formation and more severe bone loss than normal mice.